Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA3 | Q99504 | 5/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | EYA2 | O00167 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20702027 | 0.91 | EYA3 (0.72) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL20718305 | 0.87 | EYA3 (0.58) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL20702031 | 0.85 | EYA3 (0.80) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL20280639 | 0.83 | CYP2C19 (0.70) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL20718462 | 0.82 | EYA3 (0.54) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL20718301 | 0.80 | EYA3 (0.58) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL1287381 | 0.80 | SLC22A12 (0.78) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL25389800 | 0.76 | TTR (0.74) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| SCHEMBL15698033 | 0.75 | EYA3 (0.83) | EYA3SLC22A12CYP2C19TTRCYP2C9 | |
| Poztinurad SCHEMBL15698085 | 0.74 | EYA3 (1.00) | EYA3SLC22A12CYP2C19TTRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116888-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-109790135-B | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia | 广州瑞安博医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-116332886-A | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia | 广州瑞安博医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-113214198-B | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia | 广州瑞安博医药科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220112171-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220112171-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3957629-A1 | PROCESS FOR MAKING DEUTERATED HYDROXY-BENZBROMARONE AND INTERMEDIATES THEREOF | Arthrosi Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11236058-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-113214198-A | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia | 安索治疗公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20200148659-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200148659-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190169150-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169150-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10239854-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239854-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190040030-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20190040030-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236058-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-20190169150-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-20220112171-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-20240116888-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-20200148659-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-10239854-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
| US-20190040030-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885CYP2C19 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.